CYC-126 — Initial data
2027
Initial POC clinical data from this program are currently expected in 2027.Source filing
CYCN biotech catalysts & pipeline
CYCLERION THERAPEUTICS INC · Data as of 2026-10-25
Upcoming catalysts
lead program — Initial data
in 2027
A Phase 2 proof-of-concept trial for its lead program is expected to initiate in 2026, with an initial data set anticipated in 2027.Source filing
KRSA-028 — Initial data
mid-2027
Advancing lead program KRSA-028 toward the clinic, with Phase 1 healthy volunteer data expected mid-2027 and interim proof-of-concept data in Alzheimer's patients anticipated by year-end 2027 or first quarter of 2028Source filing
KRSA-028 — Interim data
Sep 2027–Mar 2028
Advancing lead program KRSA-028 toward the clinic, with Phase 1 healthy volunteer data expected mid-2027 and interim proof-of-concept data in Alzheimer's patients anticipated by year-end 2027 or first quarter of 2028Source filing